Alzheimer's Disease

Understanding Alzheimer's Disease

Alzheimer's disease is a progressive neurodegenerative condition that affects memory, thinking, and behaviour. It is the most common cause of dementia, affecting millions of people worldwide.

Mild cognitive impairment (MCI) represents an early stage where cognitive changes are noticeable but don't significantly interfere with daily functioning. Early intervention at this stage may be particularly beneficial.

Why TPS for Alzheimer's Disease

TPS is being investigated in neurodegenerative conditions, including cognitive impairment and Alzheimer's disease. Current evidence should be interpreted in the context of study design, sample size, follow-up duration and other methodological limitations. TPS should not be presented as established to slow Alzheimer's disease progression or to produce a particular cognitive improvement. Where considered, suitability is reviewed alongside standard neurological assessment and established care.

Our Treatment Approach

Our TPS programme for Alzheimer's disease begins with comprehensive assessment including QEEG brain mapping to identify specific areas of dysfunction. Treatment protocols are personalised based on individual neurophysiological profiles.

The treatment process involves:

• Initial QEEG brain mapping to assess brain function
• Development of personalised TPS protocol targeting affected regions
• Regular treatment sessions using neuronavigation guidance
• Ongoing monitoring and protocol adjustment based on response
• Support for families and caregivers

What to Expect

TPS treatment for Alzheimer's disease is a non-invasive procedure. Sessions typically last varies and are well-tolerated. The number of sessions and treatment duration will be discussed during your consultation based on the stage of the condition and individual response.

Outcomes vary between individuals, and we'll discuss realistic expectations during your consultation.